MetaCap

Nkarta (NKTX) vs Upstream Bio (UPB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Nkarta (NKTX) has outperformed Upstream Bio (UPB) over the past year, losing 36.9% versus a loss of 93.8%. Upstream Bio is the larger company by market cap ($87.2 million vs $81.3 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NKTX-36.94%UPB-93.78%
+114%+5%-104%
Nov 21, 20251 yearNov 20, 2026
NKTX-70.82%UPB-92.77%
+48%-26%-99%
Oct 7, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NKTX versus UPB key metrics
MetricNKTXUPB
Share price$1.14$1.59
Market cap$81.29M$87.15M
1-day change+1.34%-20.50%
YTD return-38.65%-94.14%
1-year return-36.94%-93.78%
5-year return-93.05%—
EPS (TTM)$-1.73$-3.01
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0$2.85M
Revenue growth (YoY)—+20.42%
Net income (latest FY)$-104.08M$-143.44M
Operating margin—-5618.82%
Net margin—-5026.03%
52-week high$3.72$33.68
52-week low$1.11$1.56
Distance from 52-week high-69.49%-95.28%
Analyst consensusstrong_buybuy
Avg. price target upside+825.11%+1245.91%
Average volume1.02M1.01M
Shares outstanding71.62M54.81M
Employees10875
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • NKTX has outperformed UPB by 56.8 percentage points over the past year.

About Nkarta

NKTX stock →

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis.

Health Care · Biotechnology: Pharmaceutical Preparations · 108 employees

About Upstream Bio

UPB stock →

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees

NKTX vs UPB FAQ

Which is bigger, Nkarta or Upstream Bio?

Upstream Bio (UPB) is larger, with a market capitalization of $87.15M compared with $81.29M for Nkarta (NKTX).

Which stock has performed better over the past year, NKTX or UPB?

NKTX returned -36.94% over the past 12 months, compared with -93.78% for UPB (price return, excluding dividends). Past performance does not predict future results.

Are Nkarta and Upstream Bio in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons